The recent revelation of two previously undisclosed deaths in Chinese gene-editing trials has renewed scrutiny of the way cutting-edge treatments are developed, and prompted U.S. lawmakers to call for limits on the use of Chinese medical trial data. In our latest Company in the News feature, The Wire China looks at BGI, the leader in China’s genetics field from research to testing and treatment development (BGI wasn’t involved in the clinical trials deaths). In June, Nature magazine ranked t
Subscribe or login to read the rest.
Subscribers get full access to:
- Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
- A weekly curated reading list on China from Andrew Peaple.
- A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our
Subscriptions page for details.
Includes images from Depositphotos.com
